Human mesenchymal stromal cells primed with paclitaxel, apart from displaying anti-tumor activity, maintain their immune regulatory functions in vitro

Cytotherapy. 2014 Jun;16(6):868-70. doi: 10.1016/j.jcyt.2014.01.414. Epub 2014 Mar 13.

Authors

Antonella Conforti¹, Simone Biagini¹, Nadia Starc¹, Alessandra Proia¹, Augusto Pessina², Giulio Alessandri³, Franco Locatelli⁴, Maria Ester Bernardo¹

Affiliations

¹ Department of Pediatric Hematology/Oncology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
² Department of Biomedical, Surgical, Dental Sciences, University of Milan, Italy.
³ UCV Neurobiology, IRCCS Neurological Institute, Carlo Besta, Milan, Italy.
⁴ Department of Pediatric Hematology/Oncology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy; University of Pavia, Pavia, Italy.

PMID: 24631286
DOI: 10.1016/j.jcyt.2014.01.414

No abstract available

Keywords: anti-tumor effect; immune modulatory properties; mesenchymal stromal cells; paclitaxel.

Publication types

Letter
Research Support, Non-U.S. Gov't
Kommentar

MeSH terms

Animals
Antineoplastic Agents / pharmacology*
Humans
Mesenchymal Stem Cells / drug effects*
Neoplasms / drug therapy*
Neoplasms / pathology*
Paclitaxel / pharmacology*

Substances

Antineoplastic Agents
Paclitaxel